Prior authorization denial rates for GLP-1 obesity prescriptions have been high, and industry reporting through 2024 put them well above half of requests in some plans
A sluggish thyroid reduces fat-burning efficiency, while chronic stress elevates cortisol levels, leading to excess abdominal fat
All this translates into an improvement in glycemic control and dyslipidemia, a reduction in blood pressure, weight, and ectopic visceral fat deposits, as well as inflammation and coagulation, which could translate into greater cardiovasculorenal protection with the use of these drugs
A systematic review and meta-analysis published in eClinicalMedicine found that discontinuing GLP-1 receptor agonist treatment led to an average weight regain of 5.63 kg and 5.81% of body weight across all patients studied
A Natural, Targeted Approach to Lasting Weight Loss How It Works: 1
Key players driving the GLP-1 market include Novo Nordisk, Eli Lilly, Pfizer, AstraZeneca, Roche, Sanofi, Boehringer Ingelheim, and Tonghua Dongbao Pharmaceutical